EFFICACY AND SAFETY OF GUSELKUMAB IN THE TREATMENT OF PLAQUE PSORIASIS
DOI:
https://doi.org/10.56320/tcdlhvn.49.258Keywords:
psoriasis, biologics, guselkumab, IL-23 inhibitorAbstract
ABSTRACT
Objectives: To evaluate the efficacy and safety of guselkumab in the treatment of patients with moderate to severe plaque psoriasis.
Materials and methods: A clinical trial was conducted on 32 patients with moderate to severe psoriasis. Patients received subcutaneous injections of guselkumab 100 mg at weeks 0, 4, 12, and 20. Treatment response was evaluated using PASI (Psoriasis Area and Severity Index) and DLQI (Dermatology Life Quality Index). Adverse events were recorded throughout the 20 weeks treatment period.
Results: After 20 weeks of treatment, both PASI and DLQI scores showed a statistically significant reduction. PASI75 and PASI90 response rates were significantly increased from week 4, immediately following the first dose, reaching 93.8% and 71.9%, respectively, at week 20. PASI100 responses were first observed at week 12 and reached 15.6% by week 20. No adverse events were reported in the study population.
Conclusion: Guselkumab demonstrates high efficacy with marginal side effects in the treatment of moderate to severe plaque psoriasis.
Received: September 25, 2024
Reviewed: October 9, 2024
Accepted: December 4, 2024
Online published: 14 September, 2025
